With 30% of the population already affected and projections soaring to 41.4% by 2050, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly emerging as the silent giant of modern chronic disease.
More than a liver issue, MASLD is now seen as a complex metabolic disease requiring collaboration across hepatology, endocrinology, primary care, nutrition, and more.
Harvard’s Dr. Christos Mantzoros says:
“We don’t have enough experts to treat these patients… We need collaboration, training, and professional societies building bridges.”